Hopes that it could be useful for treating people with mild illness have also proved unfounded. In June, a trial of Paxlovid’s effects in standard-risk Covid patients was ended when the treatment failed to significantly relieve the symptoms of those participating.
Paxlovid’s usefulness is in protecting at-risk people from experiencing the very worst effects of Covid—it isn’t used to stop people from developing symptoms altogether, nor to block an infection after someone has been exposed.
Does It Work Against the Newer Variants?
It appears so. In February 2022, Pfizer reported that nirmatrelvir was effective in halting
→ Continue reading at Wired - Science